3Z Pharmaceuticals has published a study pioneer in The Journal of Pharmacology and Experimental Therapeutics on the treatment of ADHD. Research reveals new findings on shared metabolic pathways between stimulant and non-stimulant medications. This study is key as it uses advanced metabolomics and lipidomics techniques to analyze the effects of treatments for ADHD.
Convergence of treatments and discovery of amlodipine
The study highlights the convergence of metabolic pathways between drugs such as methylphenidate, guanfacine, and atomoxetine. Furthermore, it reveals that amlodipine, a new 3Z candidate, also shares these pathways. This convergence reinforces the possibility of using L-type calcium channels as a therapeutic pathway for ADHD. According to the researchers, these findings offer a path towards new non-stimulant therapies.
Advances in treatment and future therapeutic options
The results suggest that the Current treatments for ADHD affect not only neurotransmitter metabolism, but also oxidative stress and energy metabolism.This evidence demonstrates that the drugs have a broader systemic impact than previously thought. Furthermore, amlodipine shows effects that overlap with those of established treatments, supporting its potential use in the future.
Metabolomics-based innovation for pharmacological research
3Z Pharmaceuticals has taken an innovative approach to drug discovery in the central nervous system. Using advanced analytics and the zebrafish model, the company has discovered common metabolic signatures across treatments. This approach promises to improve precision in developing new treatments for ADHD.
With these results, 3Z strengthens its drug discovery platform and advances in the creation of more effective therapies. The research also opens the door to more varied and necessary treatment options for patients with ADHD.
